Author Archives: admin


New Automation Solution to Accelerate Cell and Gene Therapy Manufacturing Announced – Labmate Online

Terumo BCTs latest cell therapy technology, the Finia Fill and Finish System, is a first-of-its-kind device developed to help bring reproducibility and control to cell therapy manufacturing to get therapies to more patients who need them.

Finia is a fully automated, modular, functionally closed system that creates the final formulation of cell and gene therapies and divides them into user-defined doses for patients. The technology automates a process that is currently manual and labour- intensive with the added risk of error.

Terumo BCT technologies have been automating the collection and processing of blood and cells for decades, said Antoinette Gawin, President and Chief Executive Officer, Terumo BCT. Now, were translating this knowledge to support technology breakthroughs in cell and gene therapies. Finia helps cell therapy developers and researchers simplify processes while increasing accuracy, consistency, reliability and reproducibility - key to securing regulatory approval.

The production and delivery of cell-based therapies is a complex and logistically challenging process, said Delara Motlagh, Vice President, Cell Therapy Technologies, Terumo BCT. Developers and manufacturers appreciate support in determining when to automate, which processes to automate and how to integrate automation into their existing process.

Finia combines, mixes and divides the final product into predetermined volumes, all under controlled, refrigerated temperature. It automatically removes air before it seals the final product bags, simplifying the downstream process. Finia also works with Terumo BCT's Cell Processing Application software in the customers' network to facilitate compliance to current good manufacturing practices (cGMP), including electronic recordkeeping, control of process workflow, user credentialing and permission, and guidance of operators through the process with an intuitive user interface module (UIM).

With Finia, we are expanding our portfolio of automation technologies aimed at this growing industry, said Motlagh. We are bringing multiphase solutions for cell and gene therapies helping to scale manufacturing and drive toward commercialisation to reach larger patient numbers.

More information online: https://ilmt.co/PL/6VaE

More here:
New Automation Solution to Accelerate Cell and Gene Therapy Manufacturing Announced - Labmate Online

Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Platform – GlobeNewswire

GAITHERSBURG, Md., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B financing. Proceeds will be used to advance the Companys ARC-T + sparX programs, including clinical development of a bivalent BCMA-targeted cell therapy in multiple myeloma, and a CD123-targeted therapy in acute myeloid leukemia. The Series B will also fund earlier stage ARC-T + sparX programs for patients with solid tumors and diseases outside oncology.

Participants in the Series B include both existing and new investors to Arcellx. New investors Aju IB and Quan Capital co-led the round, followed by Mirae Asset Venture Investment, Mirae Asset Capital, LG Technology Ventures, JVC Investment Partners, and certain funds managed by Clough Capital Partners, L.P. Existing investors Novo Holdings, S.R. One Limited, NEA and Takeda Ventures also participated in the financing.

Concurrent with the financing, Hugo Beekman, Partner at Aju IB, and Lewis (Rusty) Williams, M.D., Ph.D., Venture Partner at Quan Capital, have joined the Arcellx board of directors.

The financial and strategic support from our investors allows Arcellx to accelerate development of a robust pipeline of ARC-T + sparX programs for patients in need, commented David Hilbert, Ph.D., President and Chief Executive Officer of Arcellx. As impressive as conventional CART therapies have been, their safety and efficacy profiles are challenged by severe toxicities, high rates of relapse, and challenging target selection in the solid tumor setting. The ARC-T + sparX platform addresses these concerns by placing ARC-T cells under the control of one or more sparX proteins that uniquely determine how the ARC-T cells recognize tumor, and the speed with which ARC-T cells kill tumor. In the coming months we will begin clinical testing of our lead BCMA-targeted therapy in multiple myeloma.

Rusty Williams, M.D., Ph.D., commented, Arcellx hasreached a positive inflectionin its novel platform and pipeline with the potential to improve efficacy and safety. We are excited to support the company as it advances new cell therapies with the potential to deliver better outcomes for patients.

Hugo Beekman, Partner at Aju IB, commented, Arcellx has invented a differentiated cell therapy platform with ARC-T + sparX that allows simultaneous and sequential targeting of multiple tumor antigens. The ability of sparX proteins to reprogram the specificity of ARC-T cells has the potential to address the high incidence of tumor relapse, as well as the inherent diversity of tumor antigens expressed within solid tumors. The features of this platform, along with scalable and efficient manufacturing processes, are intended to facilitate the Companys development of new therapies in oncology, and more broadly, in autoimmune disease and the transplant setting.

About ARC-T + sparX Technology

Arcellx has pioneered a proprietary sparX + ARC-T platform in which a Soluble Protein Antigen-Receptor X-linker (sparX) simultaneously binds one or more tumor antigens and engages a universal receptor expressed on the Antigen-Receptor Complex T cells (ARC-T). The formation of a sparX + ARC-T + tumor cell complex results in tumor killing. This therapeutic platform is designed to enhance safety and efficacy while accelerating development by broadening patient accessibility and increasing efficiency of manufacturing relative to existing cell therapies.

About Arcellx, Inc.

Arcellx is a privately held biopharmaceutical company located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen-Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease.

Contact:Solebury TroutZara Lockshin (media)Tel: +1 646-378-2960Email: zlockshin@troutgroup.com

Alan Lada (investors)Tel: +1 646-378-2927Email: alada@troutgroup.com

Originally posted here:
Arcellx Raises $85 Million in a Series B Financing to Advance its Intelligent Cell Therapy Platform - GlobeNewswire

Debating the Use of MRD Testing for Treatment Decision Making – AJMC.com Managed Markets Network

Although minimal residual disease (MRD) is increasingly being used to predict treatment outcomes and as a surrogate marker of progression-free survival, there remains controversy over whether it is ready to be used in treatment decision making.

There are some scenarios when having MRD information would make management decisions easier, according to an abstract from Jeffrey L. Wolf, MD, of the University of California, San Francisco.1 One scenario is when clinicians are deciding whether or not to stop maintenance therapy. There are likely many situations in which patients are being overtreated because patients stay on prolonged maintenance therapy until progression. These therapies not only are costly, but they also have side effects.

The knowledge that a patient has achieved MRD negativity year after year would certainly help with the decision to stop therapy and not necessarily start another agent, Wolf wrote.

In another scenario, rising MRD could indicate to clinicians that the current therapy was ineffective and should be stopped and that the patient should perhaps even switch to another therapy.

In both scenarios, Wolf noted that there would be no issue to use MRD in this way if only MRD was a peripheral blood test. However, MRD testing is currently a bone marrow test, which is why it is not used more. He argued that a bone marrow procedure should not stand in the way of MRD testing being used more.

Wolf added that MRD would be helpful for clinicians deciding whether to proceed with renal allograftingpatients with persistent MRD negativity would do well to have the allograft, he wroteor whether or not to transplantnegative MRD after induction could mean a patient does just as well going to maintenance therapy rather than being subjected to transplant first.

I conclude that the time has come to begin to use MRD, along with other information, to make clinical decisions, Wolf wrote.

However, in another abstract from the meeting, Thomas Martin, MD, of the University of California, San Francisco, argues that MRD testing has not realized its true potential yet in multiple myeloma.2

Martin agreed that blood-based testing would allow for greater use of MRD testing, but it is currently not ready for primetime, and, for now, MRD assessments should only be used to evaluate prognosis.

Some remaining important questions include how many cells are needed from the bone marrow biopsy to be an adequate sample. In addition, Martin noted that cross-study comparisons remain difficult as studies report MRD-negative results in different ways. For instance, some chimeric antigen receptor T-cell therapy studies label patients as MRD negative even when they have detectable m-proteins; however, this does not align with MRD negativity as defined by the International Myeloma Working Group.

MRD results provide prognostic information only and future clinical trials with adaptive designs will define how MRD can guide treatment decisions, Martin concluded.

References

1. Wolf JL. Debate: can MRD be used for treatment decisions? Yes!!! Clin Lymphoma Myeloma Leuk. 2019;19(suppl 1):S44-S45.

2. Martin T. Multiple myeloma: minimal residual disease testingnot ready for primetime. Clin Lymphoma Myeloma Leuk. 2019;19(suppl 1):S46-S48.

See the original post:
Debating the Use of MRD Testing for Treatment Decision Making - AJMC.com Managed Markets Network

Genprex’s Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support – Business Wire

AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genprex, Inc. (NASDAQ: GNPX), a clinical-stage company and leader in gene therapy using non-viral vector transfection delivery, wishes to draw attention to additional research in the field validating non-viral vector delivery as the next evolution in gene therapy.

A recently published paper by researchers in Australia, Spain and Austria supports the belief that non-viral delivery could be safer for patients than viral vectors and could speed up the production time while reducing the costs of production. The paper titled, Encapsulation, Visualization and Expression of Genes with Biomimetically Mineralized Zeolitic Imidazolate Framework-8 (ZIF-8) published in the September 4, 2019 issue of the scientific journal Small, presents data from a biomolecule-metal-organic framework (nano MOF) in zeolitic imidazolate framework-8 (ZIF-8) and found it to be a viable vehicle for intracellular transfection and gene delivery. Genprex was not involved in the study, which used a different nanotechnology.

One of the biggest differentiators between Genprex and other gene therapy companies developing technologies to treat cancer and other serious diseases is our proprietary non-viral nanoparticle delivery system, which has already been used to safely treat more than 50 patients to date, said Genprexs Chairman and Chief Executive Officer, Rodney Varner. Most gene therapy research has been focused on using viral delivery systems to deliver genes to cancer cells, and today most approved gene therapies for non-blood cell therapies use a viral vector to deliver the gene to the patient. Our proprietary non-viral delivery system enables us to potentially treat patients with a system that may be safer, with lower production costs and better scalability.

Based on the shortcomings that viral vectors have historically had, including severe adverse reactions, high production costs, difficulty in scaling and high immunogenicity responses, Genprexs founders partnered with the National Institutes of Health (NIH) during the companys inception to develop its proprietary non-viral delivery system.

Specifically, Genprexs platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. The nanovesicles are non-immunogenic, allowing repetitive therapeutic dosing. Genprexs nanovesicles are also clinically proven to effectively deliver molecular kinase inhibitors effectively.

A Phase I human clinical trial showed that Genprexs lead drug candidate, Oncoprex immunogene therapy, which is delivered through its nanovesicle non-viral delivery system, selectively and preferentially targeted primary and metastatic tumor cells, resulting in clinically significant anticancer activity. Genprexs clinical trials have also demonstrated that its delivery system is well tolerated in humans and can safely deliver high therapeutic doses.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprexs initial product candidate, Oncoprex immunogene therapy for non-small cell lung cancer (NSCLC). Genprexs platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex on cancer and the safety, production cost and scalability of Oncoprex and its non-viral delivery system. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of Oncoprexs effect on cancer, the safety, cost and scalability of Oncoprex and its delivery system, as well as the timing and success of our clinical trials and planned clinical trials, Oncoprex and our other potential product candidates. These and other risks and uncertainties associated with Genprex and its lead product candidate Oncoprex are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Go here to see the original:
Genprex's Pioneering Use of Non-Viral Delivery for Gene Therapy is Gaining Industry Support - Business Wire

New NIH viral vector flips the script on sickle cell disease gene therapy – Endpoints News

Researchers at the NIH have rolled out a new vehicle for sickle cell gene therapy with higher speeds and better horsepower, potentially allowing vastly more efficient gene transfer and a much larger carrying capacity. The best part? Unlike current sickle cell gene therapy models, the NIH one doesnt have to drive in reverse.

In mice and monkeys, the new vehicle was up to 10 times more efficient and had a carrying capacity the amount of DNA it can haul of up to 6 times that of the conventional vectors currently deployed in gene therapy trials across the country. Most notably, the new vector can read the therapeutic gene sequence forward rather than reading them backward a counter-intuitive trick researchers had used to overcome long-running barriers to gene therapy but which sacrificed efficiency. The results were published open access inNature Communications.

Our new vector is an important breakthrough in the field of gene therapy for sickle cell disease, said study senior author John Tisdale, chief of the Cellular and Molecular Therapeutic Branch at the National Heart, Lung, and Blood Institute (NHLBI). Its the new kid on the block and represents a substantial improvement in our ability to produce high capacity, high-efficiency vectors for treating this devastating disorder.

Gene therapy trials for SCD have launched the past few years, bringing a handful of well-covered cases of patients responding strongly to the treatment, even as more data shows current techniques are no cure-all. One of the bigger longstanding questions, though, is how to best deliver the genetic fix.

The simple genetic underpinnings of the disease have been well-understood since the 1950s one A-T substitution in the -globin gene and researchers have accordingly targeted it since the first gene therapy research in the 1980s. But the particular problems of building a proper vector for the hemoglobin gene, in addition to the myriad other obstacles to gene therapy broadly, have impeded progress.

Click on the image to see the full-sized version

The lentiviral vector bluebird bio has used to bring its sickle cell gene therapy to trial is a workaround to an early problem unique to sickle cell therapy. RNA splicing a natural process critical to preparing the vector will remove introns that are key to expressing the genes to produce hemoglobin. Developers have been able to get around this by using a vector that reads the DNA backwards, last gene to first. Most gene therapy techniques read as you would a sentence, first word to last.

The researchers also noted their vectors were cheaper to produce.

More:
New NIH viral vector flips the script on sickle cell disease gene therapy - Endpoints News

Bio Innovation Conference to Highlight Cell and Gene Therapy Industry & Why Maryland is Becoming the #1 Destination for Biotech Companies -…

October 3, 2019

The cell and gene therapy field has exploded over the past few years. Fueled by innovations in immunotherapy, cell engineering and biomanufacturing, as well as landmark FDA approvals, a new era of medicine is upon us that is delivering new approaches to the treatment of cancer and other serious and life-threatening diseases.

This nascent industry is expanding all across the globe and Maryland, in particular, has seen an exponential boom within its cell and gene therapy cluster. Its this boom that Maryland Tech Council (MTC) CEO Marty Rosendale hopes to capitalize on to help Maryland rise above the likes of leading clusters such as Boston and the San Francisco Bay Area to be the number one destination for life science companies.

Rosendale is a competitive guy, and hes seen this same fire and competitive drive from many of the trade organizations 435 tech and life science members. In a recent Baltimore Business Journal article titled, Md. Tech Council CEO wants state biotech industry to aim higher than top 3, Rosendale shared, I think its time to look again, focus in on areas were already doing very well in, and aim for No. 1.

An important distinction is that Being the #1 place for companies to grow their business is different from being #1 in the rankings of GEN and JLL, he added.

Rosendale believes that Maryland, the anchor of the Biohealth Capital Region (BHCR), is already #1 for many companies due to the regions strong quality of life, close proximity to the National Institutes of Health and other research institutions and its deep talent pool.

He points to recent examples like Kite Pharma choosing to build its manufacturing site in Frederick County and the recent acquisition of Paragon Bioservices by Catalent as confirmation of the BHCRs ascending reputation as a global biohealth cluster. Add to this the regions growing cell and gene therapy industry, its blossoming immunotherapy ecosystem and a rapidly developing advanced biomanufacturing capability, and its easy to see the source of Rosendales confidence.

Success will bring more success. The more we can drive success it will build on itself and the message will become clearer and clearer. Its about getting that message out and incorporating it into the public discussion, he added.

Getting the message out and building on the regions success is what motivated Maryland Life Sciences (a division of MTC) to launch the upcoming Bio Innovation Conference, which is expected to draw a crowd of more than 400 life science professionals on Monday.

The Bio Innovation Conference is focused on cell and gene therapy this year and whats happening in this space and why its happening in Maryland, stated Rosendale.It is designed to explore what can we do, together, to help build this industry. We have panels on advanced biomanufacturing, capital markets and the science behind the industry and great keynotes in Dr. John Tisdale of NIH and Michelle McMurray-Heath of JLABS @ Washington DC, he added.

Were experiencing an exciting time in the region, with wave upon wave of innovations, collaborations, acquisitions, tech transfer and growth, said Rosendale. Companies from all over the country are moving here to experience all that Maryland and the region have to offer. This conference provides the perfect backdrop to showcase it all and discuss how to further propel us to the No. 1 spot among life sciences hubs.

Notable speakers in the cell and gene therapy/biomanufacturing space include:

In our recent podcast, Maryland Secretary of Commerce Kelly Shulz summed up what we need in one word: Stories. We need to tell stories. We need to tell people our success stories and why theyve been successful and why being in Maryland helped them succeed. The more we can tell these stories, the more we can get everyone talking about our region and thereby increase our recognition, Rosendale stated.

If you are attending the Bio Innovation Conference on Monday, youll hear dozens of success stories and will walk away with no doubt as to why biotech, particularly cell and gene therapy and biomanufacturing, is thriving in Maryland.

Over the past 8 years, Chris has grown BioBuzz into a respected brand that is recognized for its community building, networking events and news stories about the local biotech industry. In addition, he runs a Recruiting and Marketing Agency that helps companies attract top talent through a blended model that combines employer branding and marketing services together with a high powered recruiting solution.

Read the original here:
Bio Innovation Conference to Highlight Cell and Gene Therapy Industry & Why Maryland is Becoming the #1 Destination for Biotech Companies -...

Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights – P&T…

FELTON, California, Oct. 7, 2019 /PRNewswire/ -- The global Stem Cell Market was valued at US$ 8.65 billion in 2018 and is estimated to grow at an 8.8% CAGR and will touch the value of US$ 15.63 Billion by the completion of the year 2025.

During the previous insufficient years, stem cells therapy has been attaining grip all over the world. A substantial growth in the number of clinical use of stem cells and the arrival of new-fangled treatments for long-lasting sicknesses are projected to boost the development of the global stem cells market during the following insufficient years. Moreover, the growing investment by community along with private groups for research actions are expected to increase the general development of the market during the nearby future.

Classification:

The global stem cell market can be classified by Therapy, Technology, Application, Product End User, and Region. By Therapy it can be classified as Allogeneic Stem Cell Therapy, Autologous Stem Cell Therapy. The subdivision of Autologous Stem Cell therapy was the leading sector by means of generation of income in 2018. It is credited to big scale ingestion of these products owing to associative high compatibility. Furthermore, growing methodical evaluations and meta-analysis revisions on reviewing the efficiency of autologous cell therapy on treatment of lower limb illnesses will more offer thrust to the market.

By Technology it can be classified as Expansion and Sub-Culture, Cryopreservation, Cell Production, Cell Acquisition. The subdivision of Cell Acquisition technology is the elementary main step that has caused supremacy of this section. It is likely to uphold this position during the course of the forecast period, due to increasing alertness about the importance of stem cells. Bone marrow is the maximum utilized technology for cell acquisition due to the comparatively quicker manufacture of new cells from bone marrow. Additionally, cells that initiate from bone marrow are extra concentrated as equated to additional origin places.

Get Sample PDFand read more details about the "Stem Cells Market" Report 2025.

By Application it can be classified as Drug Discovery and Development, Regenerative Medicine. The subdivision of Regenerative Medicine is witnessed to grasp the prospective for creating early-intervention treatments to treat degenerative illnesses and painful injury. Additionally, obtainability of regenerative medicine through a widespread variety of clinical areas is motivating the development of the section.

By Product it can be classified as Very Small Embryonic like Stem Cells, Human Embryonic, Induced Pluripotent Stem Cells, and Adult Stem Cells. The subdivision of Adult Stem Cell detained the biggest share of the market which was prized US$ 7.38 billion in 2018. It is projected to carry on leading for the duration of the forecast. This is credited to the low-slung hazards of pollution associated to sub-culturing, negligible necessity of labor force for production and compatibility with humanoid figure. By End User it can be classified as Service Companies, Cell and Tissues Banks, Tools and Reagent Companies, Therapeutic Companies.

Regional Lookout:

By Region, the global stem cells industry can be classified as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is expected to record speedy CAGR for the duration of the forecast. The nations such as Singapore, Australia, and Japan are mainly capitalizing in the R&D projects. This is set to motivate the development of the region. Economies from Asia Pacific are likely to be at the front position of speedily developing cell industry. Issues similar to advantageous controlling strategies together with openings for commercialization increase the provincial growth. Controlling alterations relating to regenerative medication in Japan have fascinated worldwide companies to capitalize in the Japanese market.

North America is expected to carry on holding the foremost market share during the period of forecast, due to the hard work from government and private segments operational in the direction of formation of distinct business models in Canada and the U.S.A.

Companies:

The companies are opting for multidisciplinary commercial growth and multi-sector team work to safeguard incessant source of great quality pluripotent and distinguished cells. This is set to step up the rivalry, motivating the continuous necessity to present innovative products.

Some of the important companies for stem cell market are Promethera Biosciences, Human Longevity Inc., Cytori Therapeutics, BIOTIME, INC., STEM CELL Technologies Inc., Mesoblast, Cynata, Advanced Cell Technology Inc., Osiris Therapeutics Inc., and Celgene Corporation.

Browse 190 page research report with TOC on "Global Stem Cells Market" at: https://www.millioninsights.com/industry-reports/stem-cells-market

Market Segment:

Browse reports of similar category available with Million Insights:

About Million Insights:

Million Insights, is a distributor of market research reports, published by premium publishers only. We have a comprehensive market place that will enable you to compare data points, before you make a purchase. Enabling informed buying is our motto and we strive hard to ensure that our clients get to browse through multiple samples, prior to an investment. Service flexibility & the fastest response time are two pillars, on which our business model is founded. Our market research report store, includes in-depth reports, from across various industry verticals, such as healthcare, technology, chemicals, food & beverages, consumer goods, material science & automotive.

Contact:

Ryan ManuelResearch Support Specialist, USAMillion InsightsPhone: 1-408-610-2300Toll Free: 1-866-831-4085Email: sales@millioninsights.comWeb: https://www.millioninsights.com/Blog: http://www.millioninsights.blogspot.com/

See the original post here:
Stem Cells Market to Gain Huge Traction Owing to Arrival of New-Fangled Treatments for Long-Lasting Sicknesses Till 2025 | Million Insights - P&T...

New Tools in the Works to Probe Adult Human Neurogenesis – The Scientist

In March 2018, researchers reported evidence suggesting that adult humans do not generate new neurons in the hippocampusthe brains epicenter of learning and memory. The result contradicted two decades of work that said human adults actually do grow new neurons there, and revealed a need for new and better tools to study neurogenesis, Salk Institute President Fred Gage, who generated foundational evidence for adult human neurogenesis, told The Scientist at the time.

Since that study was published, several other teams have used similar techniquesbut have come to different conclusions, publishing evidence that adult humans do indeed grow new hippocampal neurons, even at the age of 99. Despite the equivocal results, Maura Boldrini, a neuroscientist at Columbia University, and a number of other neuroscientists tell The Scientist they think neurogenesis does occur in the adult human brain, bolstering learning and memory and possibly also our stress and emotional responses.

Neurogenesis is fundamentally important for the brain to react to all sorts of different insults and prevent neurological and psychiatric problems, Boldrini says. Because of its role in brain function, researchers want to learn how neurogenesis works to potentially use it to treat brain trauma, neurodegeneration, psychiatric disorders, such as depression, and possibly even the ill effects of aging.

The growth of new neurons is well studied in newborn and adult animals, especially rodents. Theres prolific neurogenesis as the brain develops, which then drops off and plateaus in adulthood, only occurring in particular areas of the brain. Examinations of human postmortem tissue suggest that the process is similar in people, based on antibody markers that label neural progenitors and young neurons. But those signals can be hard to detect in preserved cells, and the gap in time between the death of a donor and when her tissue is fixed and analyzed can affect the reliability of the markers, scientists say, which might explain the disparities in findings between different studies.

To get a reliable picture of the extent of neurogenesis in adults, scientists are pursuing a variety of new tools. Combining the direct detection techniques, such as RNA sequencing, with indirect ones, such as fMRI, Boldrini says, will indicate whats actually real when it comes to the human brains ability to make new neurons.

In a recent study, Boldrini and colleagues found that the dentate gyrus, a region of the hippocampus where neurogenesis occurs, is bigger in people who were more resilient to early life stresses, such as abuse or separation from their parents. They have more cells in the region, more neurons, and probably more neurogenesis, she says.

Of course, Boldrini notes, the study has limitations. She and colleagues were working with tissue from deceased patients brains, which brings with it the challenges of preservation and the limitations of studying dead cells. Studies in postmortem tissue have made it extremely difficult to assess whether treatments, especially in psychiatric disorders, are effective, Boldrini explains. Thats why colleagues in her department and in other labs around the world have been working to develop fMRI as a way to track neural changes that correlate with neurogenesis-related network activity in living patients.

Neurogenesis is fundamentally important for the brain to react to all sorts of different insults and prevent neurological and psychiatric problems.

Maura Boldrini, Columbia University

She and colleagues, for example, are tracking how different regions of the hippocampus in patients with depression connect with other brain regions before and after antidepressant treatment. The measurements, though, are indirect, so if the team sees increased connectivity, it cannot immediately conclude there is increased neurogenesis. You can say there is increased plasticity, Boldrini explains, which could be formed by dendrite sprouting or the making of new neurons. The same is true if the region grows in volume, which could be caused by an increase in blood capillaries or, again, the growth of new neurons. Whats generating the change cant be teased out of the results, she explains.

Studies in adult rodents have used MRI to visualize the migration of neural stem cells in the brain, but those need to be labeled with MRI contrast agents that are directly injected into neurogenic regions, a technique not suitable to use in humans.

Magnetic resonance spectroscopy, however, is non-invasive and measures biochemical changes in the body and brain. Scientists say they think it could give them a clue to how neurogenesis works in living humans, if they could identify a biomarker specific to neural stem cells or neural progenitor cells. In 2007, a team announced it had identified a metabolic biomarker that they could detect in living animals, and possibly in living humans, to track neurogenesis in vivo. That would certainly be very attractive to follow how the extent of neurogenesis is affected in an individual over time or for example in response to disease or medication, Jonas Frisn, a molecular biologist and stem cell scientist at the Karolinska Institute in Sweden, writes in an email to The Scientist. However, he says, that study has been difficult to reproduce, and that field has not taken off at all yet, unfortunately.

Another option in the works is PET imaging, a technique Yosky Kataokas team at the RIKEN Institute has been working on to identify new neuronal growth in living people. Three years ago, he and colleagues reported successfully tracking the proliferation of new cells in the neurogenic regions of rat brains using the PET tracer 3-deoxy-3-[18F]fluoro-l-thymidine and a drug called probenecid. The drug is a treatment for gout that appears to enhance the ability of the tracer to cross the blood-brain barrier. The tracer and drug together allowed the researchers to image the dentate gyrus and the subventricular zone, the two regions in adult rodents brains where neurogenesis takes place, and quantitatively visualize the neurogenic activity in the animals. The team says it is now testing the technique in adult non-human primates, with the intent to eventually use it in humans.

With PET, the challenge is to find a tracer small enough that it can be injected in the blood, pass the blood-brain barrier, and get to the brain to attach to some specific molecule that is stem-cell specific, Boldrini says. We are still trying to find markers that are stem-cell specific.

Identifying such specificity requires a more in-depth investigation of neural stem cells. The brain has tremendous heterogeneity, many, many different cell types. And if you dont look at every single cell type, you cant appreciate the complexity and heterogeneity of the brain, says Hongjun Song, a neuroscientist at the University of Pennsylvanias Perelman School of Medicine. Even the same cell type, he notes, can be in different states, so, for example, neural stem cells can be in an active state, proliferating rapidly and developing into new neurons, or a dormant state, rarely dividing and when they do, remaining as stem cells. Despite their distinct activities, cells in these different states may still express the same marker proteins, making them difficult to differentiate without single-cell analysis, such as single-cell RNA sequencing.

A three-dimensional reconstruction of nine cubic millimeters of mouse hippocampus, a part of the brain involved in memory, profiled with Slide-seq. Different cell types are shown in red, green, and blue.

Chen and Macosko labs, courtesy of Broad Institute of MIT and Harvard

The question I think were all interested in in the human brain is, do we really have cells with stem cell properties or immature neurons? I think theres probably less of a debate about whether we have those cells or not, Song says. The question is . . . are they the same as in rodents or are they very different than in rodents? Single-cell sequencing will allow us to get that kind of unbiased view.

Isolating neuronal precursor cells in the human brain isnt easy. Its much different than doing it in rodents, Song explains. In animals brains, researchers can label neuronal stem cells when the rodent is alive, and later extract and study those cells with RNA sequencing, which he and colleagues did in 2015, revealing the transcriptomes of neural stems and the cells they mature into in the adult mouse hippocampus. In humans, however, researchers again have to work with postmortem brain tissue and cant label the cells while a patient is alive. Instead, scientists have to go cell-by-cell looking for neural progenitors. The human brain, Song adds, is much larger than the mouse brain, so the cells are sparser and farther apart. You have to go through many, many cells to find them in humans, Song says.

His team and others, including Boldrinis and Frisns, have been working on RNA sequencing in postmortem human brains for several years now, and Boldrini says a new technique developed by Harvard University and MIT scientists in March might help with sorting human hippocampal nerve cells. Called Slide-seq, the technique uses genetic sequencing to draw 3-D tissue maps that identify a cells type, function, and location in tissue samples. So far, its only been tested on mouse tissue, but may hold promise for studying neural stem cells and newly made neurons, Boldrini says.

Ashley Yeager is an associate editor atThe Scientist. Email her at ayeager@the-scientist.com.

Read this article:
New Tools in the Works to Probe Adult Human Neurogenesis - The Scientist

Follow the lead of Aston Villa players and become a blood stem cell donor – 7500 To Holte

Aston Villa are a source of pride for many of us. Whether we have been life long fans or if it isa more recent obsession; once Villa grabs hold of you, it doesnt let go. The club has the history to back this up; looking at William McGregors statue and thinking about his achievements in helping setting up the league, the beauty of the Holte End and the quotes of the commentary from the European Cup win in 82 we know it has a well spring to draw on to bring pride.

Anyone with access to Facebook, Instagram or Youtube also know that the social media section of the club draw on this freely. A bombardment of hashtag #partofthepride, images of Rotterdam and videos about the club encourage us to belong, whether the club deserves it or not with its on field performances.

However the club has done something that has made me proud to be a Villan. It has led the way in a community venture which has made me live up to the clubs overused hashtag. On Saturday 20th September the club blitzed its social media with Finns story to tie in with World Bone Marrow Donor Day.

It is about a child who has a genetic disorder which causes HLH, hemophagocytic lymphohistiocytosis (lets not say that again) which affects a childs brain and body where its own white cells are attacking itself and if not treated will lead to death. This requires a Bone Marrow transplant to recover from the illness. Villa has linked up with DKMS who registered Tyrone Mings, Jack Grealish, Neil Taylor, Tom Heaton and others. They have been shown to have a simple cheek swab which takes 3 minutes and has registered the players to the world ide Bone Marrow register and encourage others to do the same.

And this is the source of my pride in Villa. I love supporting the club, sharing moments where we celebrate last minute goals, moments of individual brilliance, mocking the Blues and getting angry at being robbed or frustrated at poor performance. However Villa has given me another reason to be proud; it has lead the way in getting people signed up for the Bone Marrow Register. By doing this Villa has show it can be a club doing something for the community, for others rather than being the clich of overpaid players just in it for the money. I want to support a club that helps all of us fans support other and help other people; Villa have shown they can come up to my expectations.

I do have a vested interest in this as my daughter Isobel (the Griscelli Supergirl) also has HLH and has had for three years. She has been under Birmingham Childrens Hospital care and will need a bone marrow transplant at some point too. So thank you Villa for leading on this; I hope the Premier League, Championship and EFL all follow our example and players and fans will sign up with DKMS at events or apply on line for a kit.

If every adult fan who attended Villa Park signed up that could be tens of thousands of people who could be potential matches for Finn, Isobel or others from all over the world who need a Bone Marrow Match. Lives can be saved in that simple, 3 minute act. If all the Villans who could join, joined we would add thousands to the 27.5 million that are already on the register. The link up between DKMS and Villa could be force for good that could give exponentially.

Im Kevin and you can find me @snoggyfrokel - So please sign up via the DKMS website https://dkms.org.uk/en/register-now in the UK or for worldwide fans search for DKMS as they are in most countries.

Like our club has proved, like we prove as fans of this club #YouveGotItInYou

Originally posted here:
Follow the lead of Aston Villa players and become a blood stem cell donor - 7500 To Holte

Starving Cancer by Cutting Off Its Favorite Foods, Glucose and Glutamine – American Council on Science and Health

Your body cells, particularly neurons, love the sugar glucose. This is the reason that your body closely regulates the level of glucose in your blood. Your brain would literally starve without it. If you do not consume enough carbohydrates in your diet, your body will synthesize the glucose you need.

Unfortunately, cancer also loves glucose. It loves it so much that cancer cells are willing to burn through glucose as quickly as possible, similar to the way muscle cells burn through glucose during rigorous exercise (a process known as glycolysis). Cancer cells also supplement their "diet" with glutamine, an amino acid found in proteins.

In order to implement this metabolic shift, cancer cells put more glucose transporters (which import glucose) into their membranes and rely on glutamine to satisfy other nutritional requirements. This has led to the hypothesis that blocking the import of glucose and the metabolism of glutamine could serve as powerful weapons against cancer. In other words, starving cancer cells of their favorite foods could inhibit tumor growth.

Starving Cancer Cells of Glucose and Glutamine

Reporting in the journal Cell Chemical Biology, a team of researchers led by Elena Reckzeh describe the discovery of a new, high-potency molecule (which they called Glutor) that blocked several varieties of the glucose transport protein. This is significant because previous inhibitors were low potency and/or only blocked one kind of glucose transport protein.

The first image depicts the molecular mechanism of their proposed chemotherapeutic strategy. The first part of the strategy involves treating cancer with Glutor, which will shut down glucose metabolism. Indeed, the authors showed that 44 different cancer cell lines were potently inhibited by Glutor in vitro. Non-cancerous cell lines were not inhibited.

The second leg of their strategy involves blocking an enzyme responsible for metabolizing glutamine. When the treatments are combined, they act together to suppress cancer cell growth. (See second image. The blue region depicts the synergy of the two drugs acting in concert.)

What the Discovery Means

While this discovery is certainly very exciting, many obstacles remain. For instance, chemotherapy always has side effects, usually due to the targeting of rapidly dividing cells. It's not only cancer cells that divide quickly; so do immune cells, adult stem cells, and hair follicle cells, among many others. It is for these reasons that people on chemotherapy are usually immunodeficient and bald.

Additionally, an accompanying commentary by William Katt and colleagues indicated that there are no FDA-approved drugs that target glucose and glutamine metabolism. This is because previous drug candidates proved to be too toxic for use in humans.

So while the characteristics of Glutor are quite appealing from a pharmacologic standpoint, there is still much to prove before the drug could be available on the market.

Sources

(1) Elena S. Reckzeh et al. "Inhibition of Glucose Transporters and Glutaminase Synergistically Impairs Tumor Cell Growth." Cell Chemical Biology 26 (9) 1214-1228.E25. Published: 19-Sept-2019. doi: 10.1016/j.chembiol.2019.06.005

(2) William P. Katt et al. "Starving the Devourer: Cutting Cancer Off from Its Favorite Foods." Cell Chemical Biology 26 (9): 1197-1199. Published: 9-Sept-2019. doi: 10.1016/j.chembiol.2019.09.005

See the article here:
Starving Cancer by Cutting Off Its Favorite Foods, Glucose and Glutamine - American Council on Science and Health